Results 281 to 290 of about 58,087 (312)
Some of the next articles are maybe not open access.
2022
Prostate cancer is the most common cancer in the males. It ranks second in cancer-related deaths in the males [1]. The most common symptoms are frequent urination, difficulty in urinating, dysuria, nocturia, and hematuria even though most patients with early prostate cancer are asymptomatic.
SEMİZ, HÜSEYİN SALİH, ÖZTOP, İLHAN
openaire +4 more sources
Prostate cancer is the most common cancer in the males. It ranks second in cancer-related deaths in the males [1]. The most common symptoms are frequent urination, difficulty in urinating, dysuria, nocturia, and hematuria even though most patients with early prostate cancer are asymptomatic.
SEMİZ, HÜSEYİN SALİH, ÖZTOP, İLHAN
openaire +4 more sources
Radionuclide therapy of the thyroid
European Journal of Nuclear Medicine, 1991Radionuclide therapy has a proven place in the management of patients with thyroid disease. Iodine-131 therapy has been established as both successful and safe in treating patients with thyrotoxicosis and thyroid malignancy. Protocols for patient treatment are now standardised, although some variation in practice exists across Europe.
openaire +3 more sources
Radionuclide therapy revisited
European Journal of Nuclear Medicine, 1991Apart from its use in endocrinology and rheumatology, therapeutic nuclear medicine is developing rapidly as an additional treatment modality in oncology. Many different specific tumour-seeking radiopharmaceuticals are being applied both for diagnostic scintigraphy and treatment, using multiple routes and mechanisms to target radionuclides at tumours ...
openaire +3 more sources
Annals of Nuclear Medicine, 1998
Therapeutic nuclear medicine is rapidly developing as an additional treatment modality in oncology. Its unique characteristics are the systemic, yet selective delivery of radiation doses in target tissues, its non-invasiveness, the relative lack of immediate and late side effects, and the advantage that uptake and retention in the tumor can be pre ...
openaire +3 more sources
Therapeutic nuclear medicine is rapidly developing as an additional treatment modality in oncology. Its unique characteristics are the systemic, yet selective delivery of radiation doses in target tissues, its non-invasiveness, the relative lack of immediate and late side effects, and the advantage that uptake and retention in the tumor can be pre ...
openaire +3 more sources
Radionuclide Therapy for Neuroendocrine Tumors
Current Oncology Reports, 2017Peptide receptor radionuclide therapy (PRRT) is a form of systemic radiotherapy that allows targeted delivery of radionuclides to tumor cells expressing high levels of somatostatin receptors. The two radiopeptides most commonly used for PRRT, 90Y-DOTATOC and 177Lu-DOTATATE, have been successfully employed for more than a decade for the treatment of ...
CIVES, MAURO, Strosberg, Jonathan
openaire +4 more sources
Recent advances in radionuclide therapy
Seminars in Nuclear Medicine, 2001A variety of radionuclides continue to be investigated and/or clinically used for different therapeutic applications in nuclear medicine. The choice of a particular radionuclide with regard to appropriate emissions, linear energy transfer, and physical half-life is dictated to a large extent by the character of the disease (eg, solid tumor or ...
Ekaterina Dadachova +3 more
openaire +3 more sources
Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals, 2013Radionuclide therapy (RNT) based on the concept of delivering cytotoxic levels of radiation to disease sites is one of the rapidly growing fields of nuclear medicine. Unlike conventional external beam therapy, RNT targets diseases at the cellular level rather than on a gross anatomical level.
M. R. A. Pillai +2 more
openaire +3 more sources
Radionuclide therapy of hematologic disorders [PDF]
Seminars in Nuclear Medicine, 1979 32P is effective therapy for polycythemia and primary thrombocytosis. The Polycythemia Vera Study Group is comparing radioactive phosphorus with alkylating agents to determine relative efficacy. Less well investigated is the effectiveness of 32P vs. busulfan in chronic granulocytic leukemia. Endolymphatic administration of radiopharmaceuticals may play
openaire +2 more sources
Targeted Radionuclide Therapy of Melanoma
Seminars in Nuclear Medicine, 2016An estimated 60,000 individuals in the United States and 132,000 worldwide are yearly diagnosed with melanoma. Until recently, treatment options for patients with stages III-IV metastatic disease were limited and offered marginal, if any, improvement in overall survival. The situation changed with the introduction of B-RAF inhibitors and anti-cytotoxic
Ekaterina Dadachova, Abdullah Norain
openaire +2 more sources
2009
Most patients with advanced cancer develop metastatic bone disease; this untreatable evolution of the disease weights heavily on cancer-related mortality and morbidity. Although bone metastases are often clinically silent, some conditions may support bone pain.
openaire +1 more source
Most patients with advanced cancer develop metastatic bone disease; this untreatable evolution of the disease weights heavily on cancer-related mortality and morbidity. Although bone metastases are often clinically silent, some conditions may support bone pain.
openaire +1 more source